摘要
目的分析尼卡地平与拉贝洛尔治疗重度妊娠期高血压的临床疗效。方法本文总共纳入120例研究对象,均为2020年1月-2021年12月在我院治疗的重度妊娠高血压患者,采用电脑盲选法进行分组,分为对照组(拉贝洛尔,n=60)与研究组(尼卡地平,n=60)。对比分析两组的高血压与妊娠结局,统计两组的血清指标。结果在收缩压与舒张压水平上,研究组低于对照组(P<0.05)。在妊娠不良结局发生率上,研究组高于对照组(P<0.05)。在血清基质金属蛋白酶-9(MMP-9)、水通道蛋白-9(AQP-9)、同型半胱氨酸(Hcy)以及胱抑素C(Cys-C)上,研究组低于对照组(P<0.05)。结论相较于拉贝洛尔,尼卡地平用于重度妊娠期高血压的效果理想,对于血压水平的改善具有促进作用,有利于提高临床疗效,临床可进一步推广运用。
Objective To analyze the clinical efficacy of Nicardipine and Labelol on severe pregnancy hypertension.Methods A total of 120 subjects were included,all of whom were treated in our hospital from January 2020 to December 2,2021,grouped by computer blind selection,including the control group(Labelol,n=60)and the research group(Nicardipine,n=60).The hypertension and pregnancy outcomes of the two groups were compared and analyzed,and the serum indexes of the two groups were counted.Results At the systolic and diastolic pressure levels,the study group was lower than the control group(P<0.05).In the incidence of adverse pregnancy outcomes,the study group was higher than the control group(P<0.05).In serum matrix metalloproteinase-9(MMP-9),aquaporin-9(AQP-9),homocysteine(Hcy)and cystatin C(Cys-C),the study group was lower than the control group(P<0.05).Conclusion Compared with Rabelol,Nicardipine is ideal for severe pregnancy hypertension and improved clinical efficacy and further application.
作者
谢小敏
XIE Xiaomin(Heyuan City Longchuan County Tongqu Town Health Center,Heyuan,Guangdong 517376)
出处
《智慧健康》
2022年第1期116-118,122,共4页
Smart Healthcare
基金
河源市科技计划项目申报书(技术开发类)项目(编号:190630231503502)
